There were 52 press releases posted in the last 24 hours and 172,236 in the last 365 days.

Cidara Therapeutics to Report Third Quarter 2017 Financial Results and Provide Corporate Update

/EIN News/ -- SAN DIEGO, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it will report third quarter 2017 financial results after the close of U.S. financial markets on November 8, 2017. Cidara’s management will host a webcast and conference call at 4:05 p.m. EST/1:05 p.m. PST that day to discuss the financial results and provide a corporate update.

The live call may be accessed by dialing 844-358-8763 for domestic callers, or 703-736-7375 for international callers, and use the conference ID # 2899958. The webcast will be made available on Cidara’s website at www.cidara.com under the News and Events tab in the Investors section. Following the live audio webcast, a replay will be available on Cidara's website for approximately 30 days.

About Cidara Therapeutics

Cidara is a clinical-stage biotechnology company focused on developing new anti-infectives that have the potential to transform the standard of care and save or improve patients’ lives. The company is currently advancing its novel echinocandin antifungal, CD101 IV, through Phase 2 and developing CD201, its bispecific antibiotic immunotherapy, for the treatment of multi-drug resistant Gram-negative bacterial infections. CD101 IV has improved pharmacokinetics compared to existing echinocandins and has the potential for expanded utility across patient settings. CD101 IV is the only once-weekly product candidate in development for the treatment and prevention of life-threatening invasive fungal infections. CD201 is the first drug candidate selected from Cidara’s novel Cloudbreak™ platform, the first immunotherapy discovery platform designed specifically to create compounds that directly kill pathogens and also direct a patient’s immune cells to attack and eliminate bacterial, fungal or viral pathogens. Cidara has received a grant for up to $6.9 million from CARB-X (Combating Antibiotic Resistant Bacteria Accelerator) to advance the development of CD201 and back-up candidates. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.

INVESTOR CONTACT:
Robert H. Uhl
Westwicke Partners, LLC
Managing Director
(858) 356-5932
Robert.Uhl@westwicke.com

MEDIA CONTACT:
Christy Curran
Sam Brown Inc.
(615) 414-8668
ChristyCurran@sambrown.com